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Abstract: One of the most effective ways to prevent the spread of the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) is to develop accurate and rapid diagnostic tests. There are a
number of molecular, serological, and imaging methods that are used to diagnose this infection in
hospitals and clinical settings. The purpose of this review paper is to present the available approaches
for detecting SARS-CoV-2 and address the advantages and limitations of each detection method.
This work includes studies from recent literature publications along with information from the
manufacturer’s manuals of commercially available SARS-CoV-2 diagnostic products. Furthermore,
supplementary information from the Food & Drug Administration (FDA), Centers for Disease Control
and Prevention (CDC), and World Health Organization (WHO) is cited. The viral components
targeted for virus detection, the principles of each diagnostic technique, and the detection efficiency
of each approach are discussed. The potential of using diagnostic tests that were originally developed
for previous epidemic viruses is also presented.
Keywords: COVID-19; SARS-CoV-2; diagnostic tests; viral infections; disease detection
1. Introduction
An outbreak of a new pathogenic virus, the severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2), was identified in China in mid-December 2019 and spread globally [1]. This new virus,
which has a similar structure to the virus related to the SARS epidemic in 2003, was identified from a bat
species. In a previous phylogenetic study by Mackenzie et al. (2020), the virus associated with the 2019
coronavirus disease (COVID-19) pandemic shares approximately 80% of its nucleotide genome with
SARS-CoV [2]. Specifically, two previous SARS-CoV viruses, one identified from Chinese horseshoe
bats (Rhinolophus sinicus) in Zhoushan and the other identified from an Intermediate horseshoe bat
(R.affinis), shared 89% and 96% of their nucleotide genomes, respectively, with SARS-CoV-2 [2–4]. Due to
the similarity between the two viruses, the 2019-nCoV virus was named SARS-CoV-2. Even though,
the intermediate host has not been confirmed, several possible hosts include snakes, pangolins, turtles,
or other wild animals [5].
According to a WHO report, this new virus is transmitted through respiratory droplets or close
contact of patients with COVID-19 [6]. As of 30 September 2020, there have been 48 million confirmed
cases of COVID-19 around the world [7]. On the same date, CDC databases reported that there had
been 9,268,818 confirmed cases and 230,893 deaths in the United States [8]. Governments around the
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world have established social distancing requirements, travel restrictions, and mandatory quarantines
to prevent the spread of the virus. Despite these efforts, the virus has continued to spread, and the
pandemic has severely impacted the living and working conditions of people across the globe.
A large number of people have lost their jobs, and incidents of domestic violence, such as physical,
emotional, and sexual abuse, have rapidly increased. According to the US Bureau of Labor Statistics,
the unemployment rate in September 2020 was 7.9%. This rate is significantly higher than the rates
observed over the last five years, which ranged from 3.5% to 5.5% [9]. Based on data recorded by
domestic abuse charities in the UK, the number of emergency calls related to domestic abuse have
increased by 25% since the lockdown announcement [10]. Many businesses throughout the world
economy, including those in the electronic, travel, and financial industries have been shut down or
heavily restricted [11]. Therefore, to ease the severity on social and economic impacts as a result of the
COVID-19 pandemic, efforts should be put in the development of rapid and reliable technologies to
timely detect and reduce the spread of the virus to ease our way back to normality.
Some of the challenges associated with the detection of SARS-CoV-2 include the abundance of
asymptomatic cases and the difficulty of symptom recognition. Asymptomatic carriers, who may
not recognize that they are infected can still spread the virus by close contact with other people.
According to a report by Mizumoto et al., 18% of the positive cases on the Diamond Princess cruise
ship were identified as asymptomatic [12]. The basic reproductive number (R0) for the cruise ship
outbreak was 4 times higher than the productive number observed in Wuhan [12,13]. In another report
on 217 passengers on an Argentinian expedition cruise ship, 57% of passengers tested positive for
COVID-19. Of the passengers with the virus, 81% were asymptomatic [14]. These statistics suggest
that the actual number of people who have contracted the SARS-CoV-2 virus might be significantly
higher than the number that has been reported.
The second challenge in detecting SARS-CoV-2 is the difficulty of identifying and recognizing
the symptoms. In the early stages of the COVID-19 outbreak, the virus was detected by looking for
symptoms such as fever, dry cough, and shortness of breath. In 2020, Wang et al. studied 138 novel
coronavirus-infected pneumonia (NCIP) patients in a Wuhan hospital [15]. The study found that 98.6%
patients experienced fever, 69.6% patients experienced fatigue, and 59.4% of patients experienced a dry
cough [15]. These symptoms can be the same as those for other respiratory illnesses such as the common
cold, influenza, and seasonal allergies. The similarity of symptoms between COVID-19 and other
respiratory illnesses makes it difficult to recognize a SARS-CoV-2 infection. Moreover, the incubation
period of the virus varies greatly between people. As a result, many patients may not recognize that
they are infected for some time. Based on a CDC report, the symptoms of an infected person usually
appear 5 days after infection occurs [16]. It is possible, however, for symptoms to appear anytime
between 3 and 14 days after infection [16]. Due to these issues, the development of efficient, rapid,
and reliable tests for mass testing of populations can improve early detection and significantly decrease
further spread of the virus.
The SARS-CoV-2 detection techniques currently used by advanced laboratories and commercial
companies fall into three categories: (i) Molecular methods capable of detecting viral RNA sequences,
(ii) rapid diagnostic tests (RDT) that can detect the presence of the virus based on antigens or host
antibodies, and (iii) imaging techniques that can detect changes in the lung. In the molecular approach,
polymerase chain reaction (PCR)-based and high-throughput sequencing technologies are commonly
used to replicate nucleic acids and detect the presence of the virus in respiratory samples [17]. In RDT
tests, either antigens or antibodies are used to detect the presence of the virus. For antibody-based
testing, ELISA or immune-based technologies are used to detect antibodies in patient samples and
determine whether a patient was previously infected. Antibody tests are performed using blood,
plasma, or serum samples. Antigen-based testing methods can detect the presence of viral antigens
in respiratory samples and diagnose an active infection. Lastly, radio-imaging methods, such as
computed tomography (CT), are used to monitor the shape of the chest over the course of an infection.
Table 1 presents various testing methods and evaluates them based on the testing materials, detection
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platforms, detection targets, and limits of detection. These methods are also evaluated for sensitivity,
specificity, and accuracy in Table 2. Table 3 summarizes the currently available antigen-based tests for
SARS-CoV-2. This review will discuss the principles, advantages, and disadvantages of each approach.
Additionally, this paper will discuss detection approaches that were used for previous epidemic viruses
to demonstrate the possibility of their use in the detection of SARS-CoV-2.
Table 1. Available laboratory-based molecular, serological, and immunological diagnostic test for the
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Techniques Testing Materials Platform
The Amount of
Sample/
Sample Size
Detection
Workflow
Detection
Target
Limit of
Detection
(LOD)
RT-PCR [18]
Sputum, nose, and
throat swabs with
and without viral
transport medium
Nucleic
acid
RdRp genes 3.6 copiesper reaction
E genes 3.9 copiesper reaction
N genes 8.3 copiesper reaction
RdRp-P2 21.3 copiesper reaction
RdRp-Hel 11.2 copiesper reaction
Real time
RT-PCR [19]
Tear and
conjunctival
secretion
Nucleic
acid
21 patients with
common-type and
nine patients in
severe symptoms
Viral RNA in
conjunctivitis N/A
RT-LAMP [20] Viral RNA Nucleicacid N/A N/A Primer probe
LOD in the
optimization:
100
copies/reaction
in triplicate
Lateral flow
immunoassay [21] Human blood
IgG/IgM
Antibody
525 cases
including 397
positive tests
confirmed with
PCR and 128
non-infected tests
Around 15
min
Spike
protein N/A
Isothermal
LAMP-based [22] Respiratory samples
Nucleic
acid
ORF1ab
gene 17 copies/µL
ELISA [23]
Plasma samples
from healthy blood
donors, organ
donors, plasma
samples from upper
respiratory tract
swab
IgG/IgM
antibody
90 samples
including 50
negative and 40
positive
90 min for
observance
5–6 h
Spike
protein
LFIA [23] IgG/IgMantibody
39–165 individual
plasma samples
Sandwich ELISA
[24]
Pulmonary
sarcoidosis after
ablation
IgG/IgM
antibody
Nucleocapsid
protein 100 ng/mL
CRISPR-Cas12
[25] Saliva samples
Nucleic
acid
RNA
fragments
with RdRp,
ORF1b, and
ORF1ab
genes
ORF1ab:
10 copies/µL
Proteome
Microarray [26] Serum samples Antibody Antibodies 94 pg/mL
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Table 2. The general list of cross-reactivity result that have been tested from diagnostic tests.
Technique Platform Target Sensitivity Specificity Accuracy
PPV NPV
Alinity I SARS-CoV-2
IgG (Abbott)
High-
throughput
CMIA
Nucleocapsid 100% 99.9% 84% 100%
Architect SARS-CoV-2
IgG (Abbott)
High-
throughput
CMIA
Nucleocapsid 100% 99.6% 92.9% 100%
Anti-SARS-CoV-2
Rapid Test (Autobio) Lateral flow Spike
IgG: 99.0%
IgM: 95.7%
Combined: 99.0%
IgG: 99.4%
IgM: 99.7%
Combined: 99%
84.4% 99.9%
Platelia SARS-CoV-2
Total Ab (Bio-Rad
Laboratories, Inc.)
ELISA Nucleocapsid 92.2% 99.6% 91.7% 99.6%
qSARS-CoV-2 IgG/IgM
Rapid Test (Cellex, Inc.) Lateral Flow
Spike and
Nucleocapsid 93.8% 96.0% 55.2% 99.7%
DPP COVID-19
IgM/IgG System
(Chembio Diagnostic
Systems, Inc.)
Lateral Flow
with Reader Nucleocapsid
IgM: 77.4%
IgG: 87.1%
Combined: 93.5%
Combined:
94.4% 46.8% 99.6%
LIAISON SARS-CoV-2
S1/S2 IgG (DiaSorin)
High-
throughput
CMIA
Spike 97.6% 99.3% 88% 99.9%
SARS-CoV-2 ELISA IgG
(EUROIMMUN) ELISA Spike 90.0% 100% 100% 99.5%
COVID-19 ELISA
Antibody Test (Mount
Sinai Hospital Clinical
Laboratory)
2-Step
ELISA Spike Combined: 92.5% 100% 100% 99.6%
VITROS
Anti-SARS-CoV-2 IgG
test (Ortho-Clinical
Diagnostics, Inc.)
High-
Throughput
CLIA
Spike IgG: 90.0% IgG: 100% 100% 99.5%
VITROS
Immunodiagnostic
Products
Anti-SARS-CoV-2 Total
Reagent Pack and
Calibrator
(Ortho-Clinical
Diagnostics, Inc.)
High-
Throughput
CLIA
Spike 100% 100% 100% 100%
Elecsys
Anti-SARS-CoV-2
(Roche)
High-
Throughput
ECLIA
Nucleocapsid 100% 99.8% 96.5% 100%
New York SARS-CoV
Microsphere
Immunoassay for
Antibody Detection
(Wadsworth Center,
New York State
Department of Health)
MIA Nucleocapsid 88% 98.8% 79.4 99.4%
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Table 3. Summary of most recent Emergency Use Authorization (EUA) issued antigen tests for
SARS-CoV-2. All the information is collected from the Food, Drug and Administration (FDA) website.
Organization Test Name Test ResultTime
Specimen
Type LOD Characteristics
Access Bio,
Inc.
CareStart
COVID-19
Antigen test
10 min
Direct
Nasopharyngeal
Swab
8 × 102
TCID50/mL
SARS-CoV-2 Nucleocapsid
Protein-Specific, Lateral Flow,
Visual Readout, Lab-based,
Point-of-Care Testing (POC) but
requires a sample preparation
step and a trained operator to
perform the test.
Quidel
Corporation
Sofia 2 Flu +
SARS Antigen
FIA
15 min
Direct Nasal or
Nasopharyngeal
Swabs
4.17 × 105
TCID50/mL
Mulitiplex Detection
(SARS-CoV-2, Influenza A Virus,
and Influenza B Virus),
Nucleocapsid Protein-Specific,
SARS-CoV, and SARS-CoV-2
Detection but cannot differentiate
between them, Lateral Flow,
Instrument-based
Immunofluorescence Read,
Lab-based, POC Testing but is
limited to Sofia 2 Instrument for
results, Trained Operator
required.
Abbott
Diagnostics
Scarborough,
Inc.
BinaxNOW
COVID-19 Ag
Card
15 min Direct NasalSwab
22.5
TCID50/swab
Singleplex SARS-CoV-2
Detection, No Specific to
SARS-CoV-2 Detection alone
(SARS-CoV Cross-reaction),
Nucleocapsid Protein-Specific,
Lateral Flow Immunoassay,
Visual Colorimetric Pink/Purple
Read but results interpretation is
limited to individuals with
color-impaired vision, POCT
Testing but testing performance
is limited by following
meticulous testing instructions.
Lumira Dx
UK Ltd.
Lumira Dx
SARS-CoV-2
Ag Test
12 min Direct NasalSwab 32 TCID50/mL
Single-Use Microfluidic
Fluorescence Immunoassay,
SARS-CoV-2 Nucleocapsid
Protein-Specific, Digital
Instrument Read, Small Sample
Testing Volume (one drop), POC
Testing but limited to Healthcare
Professional-Use-Only proficient
in performing tests using the
Lumira Dx Platform, Requires
Lumira Dx Test Strip.
Becton,
Dickinson,
and
Company
(BD)
BD Veritor
System for
Rapid
SARS-CoV-2
Detection
15 min Direct NasalSwab
1.4 × 102
TCID50/mL
Chromatographic Immunoassay,
SARS-CoV-2 Nucleocapsid
Antigen-Specific, Digital
Instrument Reading, Result
Documentation Capabilities,
Good Analytical Sensitivity,
Laboratory-based, POC Testing
but is limited to patient testing
environments where test
interpretation can only be done
with the BD Veritor Plus
Analyzer Instrument.
Diagnostics 2020, 10, 905 6 of 28
Table 3. Cont.
Organization Test Name Test ResultTime
Specimen
Type LOD Characteristics
Quidel
Corporation
Sofia SARS
Antigen FIA 16 min
Direct Nasal or
Nasopharyngeal
Swabs
1.13 × 102
TCID50/mL
Immunofluorescent Sandwich
Assay, Lateral Flow, Singleplex
Detection, SARS-CoV or
SARS-CoV-2 Nucleocapsid
Antigen-Specific but does not
differentiate between them,
Instrument Reading, Good
Analytical Sensitivity, Results
Affected by High Viscous
Samples, Result interpretation
limited to trained clinical
laboratory personnel proficient
in performing tests using Sofia
and Sofia 2 instruments.
2. Components of SARS-CoV-2 Used for Detection
The SARS-CoV-2 virus, which belongs to the beta-coronavirus group, is described as a large,
enveloped virus with a genome made up of positive, single-stranded RNA molecules. The virus can
infect humans and other animals, and the size of its genome is approximately 29.9 kb [17]. A schematic
diagram of the SARS-CoV-2 virus is shown in Figure 1.
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2.1. Non-Structural Proteins
The genome of SARS-CoV-2 includes a variable number of open reading frames (ORFs) starting at
the 5′-end. In the first ORF, more than two-thirds of the genetic sequence encodes 16 non-structural
proteins (nsps). The remaining ORFs encode accessory proteins (HE, 3a/b, and 4a/b proteins) and
structural proteins [27,28]. In the ORF1ab region, the RNA-dependent RNA polymerase (RdRp) enzyme,
which is indispensable during genome replication, conjugates with nsps to maintain the accuracy of
the genome [28,29]. During the synthesis of viral RNA, the ORFs regions (RdRp, Hel) can be used as
catalysts to improve the replication and transcription cycles of SARS-CoV-2. Therefore, these ORFs
regions have become potential targets for the detection of SARS-CoV-2 with nucleic acid testing methods.
2.2. Structural Proteins
Theβ-coronavirus contains four structural proteins: Spike surface glycoproteins (S), small envelope
proteins (E), matrix membrane proteins (M), and nucleocapsid proteins (N). S proteins, which are
located at the outer surface of the virus, contain three segments: A large ectodomain, a single-pass
transmembrane anchor, and a short intracellular tail. These ectodomains are divided further into two
domains: The N-terminal domain (S1) and the C-terminal domain (S2) [30]. S proteins enable the
virus to enter the host cells. Human angiotensin-converting enzyme 2 (ACE2), which is found on the
surfaces of many cell types, is a host receptor for SARS-CoV-2. Human ACE2 plays one of the most
significant roles in viral entry. The S proteins bind to a host receptor through the receptor-binding
domain (RBD) in the S1 subunit and fuse the viral and host membranes through the S2 subunit [31].
As a result, S proteins can be potential targets for detecting the presence of SARS-CoV-2. The spike
proteins on the SARS-CoV-2 virus are very similar to those found on the SARS-CoV virus. According to
a report completed by Wang et al., the spike proteins of SARS-CoV shared 92% of their identity with
the SARS-CoV-2 spike proteins [32]. Therefore, interference testing needs to be completed when using
S proteins as the detection targets.
N proteins are critical for early viral replication in the host cells. N proteins play a primary role in
packaging viral RNA into ribonucleoprotein (RNP) complexes called nucleocapsids [33]. When the
virus enters the host cells, nucleocapsid proteins support the replication of viral RNA and release virus
particles into the host cells [34,35]. Due to the importance of N proteins for viral replication, they can
be used in the development of diagnostic tests for SARS-CoV-2. Based on the location and function of
these proteins, both S and N proteins have become potential targets for detecting SARS-CoV-2 related
antigens and antibodies. Additionally, S and N proteins can be helpful for identifying changes in the
virus’ genome sequence over the course of an infection.
2.3. Antibodies
An antibody or immunoglobin (Ig), which is considered a protective protein, is produced as part
of an immune response to an antigen. One method that can be used to determine a COVID-19 infection,
is the detection of antibodies (IgM, IgG, and IgA) in the body. IgM, which accounts for approximately
10% of human immunoglobin, is the first antibody produced by B cells after infection occurs [36]. It is
also the first antibody that is secreted to the blood stream during an immune response [37]. IgM has a
pentameric structure with five Y-shaped molecules and a high affinity for specific antigens [36]. IgG is
the second antibody produced during an immune response. It accounts for approximately 70–75%
of human immunoglobin found in the body and plays a significant role in developing long-term
immunity [36]. IgA, which accounts for 10%–15% of human immunoglobin, can be found in serum,
nasal mucus, saliva, breast milk, etc. [36]. Both IgG and IgM are used to determine whether a person is
currently infected or was previously infected by SARS-CoV-2. These immunoglobins are used because
they are the first antibodies produced and are found in large quantities in the human body. IgA can
also be used as a target for the detection of SARS-CoV-2, but its use is less common [38,39].
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2.4. Interleukin-6
Pleotropic cytokine, commonly known as interleukin-6 (IL-6), plays a significant role in innate and
adaptive immunity [40]. It is produced after a SARS-CoV-2 infection as a result of damage to stromal
cells and immune system cells (B lymphocytes, T lymphocytes, macrophages, monocytes) [41,42].
IL-6 modulates the host immune response and indicates the presence of extreme inflammation [40].
The concentration of IL-6 in the blood can provide insight into the severity of sepsis, septicemia,
and infection in patients who require intubation and mechanical ventilation [43–45]. According to
a study by Herold et al., respiratory failure was 22 times more severe when COVID-19 patients had
IL-6 levels greater than 80 pg/mL [44]. Therefore, IL-6 is an effective biomarker for measuring the
progress of a COVID-19 infection. Companies such as Beckman Coulter, Inc. and Roche Diagnostic
have completed development work and received Emergency Use Authorization (EUA) from the FDA
for in vitro diagnostic tests for IL-6. In these tests, IL-6 will serve as a biomarker for monitoring the
severe inflammatory response in patients with a confirmed COVID-19 infection [46].
2.5. Glycans
Glycans, which are long chains of sugar molecules, are known to be one of the main components
of the outermost surface of the virus. In the viral S protein, an examination of 66 glycosylation sites
revealed that SARS-CoV-2 glycoproteins can contain up to 10 different glycans [47]. The structure
of the glycans and the mechanism of glycan binding depends on the interaction between the viral
pathogens and the hosts cells [48]. Glycans play a significant role in the binding of the virus to the
host cell, and they can serve as biomarkers for recognizing a SARS-CoV-2 infection [49]. In a previous
report about the swine zoonotic pandemic, it was found that porcine viral hemagglutinins can switch
the binding sites in sialic acids [50]. This result demonstrates the significant role of glycans-binding
during an infection. With an understanding of the unique structure of glycans found on SARS-CoV-2,
glycans stand as a potential biomarker for the detection of the SARS-CoV-2 virus.
3. Factors that Affect the Development of Diagnostic Tests for SARS-CoV-2
3.1. Materials Evaluation
A variety of samples, including those collected from the respiratory tracts, saliva, blood, and
plasma, have been used for SARS-CoV-2 detection. Typically, non-invasive samples are collected from
the upper respiratory tract (nasopharyngeal swabs (NP), oropharyngeal swabs (OP), anterior nasal
swabs, mid-turbinate swabs, nasopharyngeal washes, and nasal aspirates) or the lower respiratory tract
(sputum, BAL fluid, and tracheal aspirates) [18,19,51,52]. NP swabs and OP swabs are recommended
for detecting the SARS-CoV-2 virus in the early stages of infection [53]. The average viral load for
both swabbing techniques during the first 5 days of infection is in the range of 6.76 × 105 copies per
swab [54]. The viral load reaches a peak of 7.11 × 108 copies per swab on day 5 [53,54]. No positive
results were received from nucleic acid tests that were done using 27 urine samples and 31 serum
samples [53]. In addition to molecular assays, rapid diagnostic tests, such as antigen testing methods,
also use nasopharyngeal samples to detect the presence of SARS-CoV-2. Therefore, these swab samples
are effective materials for detecting the SARS-CoV-2 virus during an active infection.
In contrast to the molecular approach, blood and plasma samples are typically used for serological
tests. The viral concentration in the specimens gradually changes over time because of viral replication.
The time dependency of the viral load concentration is a limitation associated with serological methods.
In an experiment that tested 535 plasma samples from 173 infected patients, it was found that the
concentration of antibodies increases shortly after an infection [36]. The median time for presenting the
counts for total antibodies (Ab), IgG, and IgM was day 11, 12, and 14, respectively [36]. One week after
symptom onset, the sensitivities of the antibody measurements were <40%. This percentage increased
to 100% (Ab), 94.3% (IgM), and 79.8% (IgG) after 15 days [36]. Antigen tests use S and N proteins as
the main viral antigen targets. A positive antigen test indicates an active infection. In the antibody
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detection approach, the IgG, IgM, and IgA antibodies related to SARS-CoV-2 are qualitatively detected.
In addition, inflammatory biomarkers, such as interleukin-6 (IL-6), can be detected in COVID-19
patients. Therefore, blood and plasma samples can be used to indicate an active or previous infection
in a patient.
3.2. Sensitivity, Specificity, and Accuracy
Currently, there is no universal testing kit for the detection of the SARS-CoV-2 virus, and different
kits use different units of measurement. In many commercial testing kits and advanced laboratories,
the success of a diagnostic test has been evaluated based on sensitivity, specificity, and accuracy.
Sensitivity is defined as the probability that a positive result will be found when the SARS-CoV-2 virus
is present in a sample. Specificity is defined as the probability of receiving a negative result when
the SARS-CoV-2 virus is not present in a sample. Both sensitivity and specificity are calculated by
the equations:
Sensitivity =
TP
TP + FN
Specificity =
TN
FP + TN
where TP is true positive, FN is false negative, TN is true negative, and FP is false positive.
Some testing kits use the positive predictive value (PPV) and negative predictive value (NPV)
to indicate the probability of a non-infected patient receiving a positive or negative test result,
respectively [55].
4. Diagnostic Tests for Detection of SARS-CoV-2
A summary of the current techniques, sample materials, specific targets, and limits of detection
(LOD) used by laboratories and biotechnology companies is presented in Tables 1 and 2. There are two
main approaches for detecting SARS-CoV-2. In the nucleic acid approach, the viral genome sequence
is used to detect the SARS-CoV-2 virus. Different targets include the E gene, S gene, and Orf1ab gene.
In the serological approach, both antigen and antibody tests are used. Antigen tests use S and N
proteins as the main viral antigen targets. A positive antigen test indicates an active infection. In the
antibody detection approach, the IgG, IgM, and IgA antibodies related to SARS-CoV-2 are qualitatively
detected. This type of serological test can indicate a previous infection. In addition, inflammatory
biomarkers, such as interleukin-6 (IL-6), can be detected in COVID-19 patients. Other emerging
methods include imaging techniques and microfluidic devices.
4.1. Molecular Assays for Detection of Viral Nucleic Acids
Based on the available genetic sequence for SARS-CoV-2, viral ribonucleic acid (RNA) can be
detected. Common methods for viral RNA detection include polymerase chain reaction (PCR)-based
technologies, isothermal amplification techniques, CRISPR-based platforms, and high throughput
sequencing technologies. These types of nucleic acid tests have become the most common methods
used in CDC and clinical laboratories for the detection of SARS-CoV-2. The number of commercial
companies that use different types of nucleic acid approaches for the detection of SARS-CoV-2 is
shown in Table 1. The majority of samples used for nucleic acid testing are collected from the upper
respiratory tract (nasopharyngeal swabs, oropharyngeal swabs, nasopharyngeal washes, and nasal
aspirates) or the lower respiratory tract (sputum, BAL fluid, and tracheal aspirates).
4.1.1. Polymerase Chain Reaction (PCR)
PCR-based technologies, which are molecular methods used for the detection of SARS-CoV-2,
are able to amplify a few copies of small viral DNA/RNA segments into millions of copies [18].
The nucleic acid segments used in the tests come from specimen samples collected from the upper and
lower respiratory tracts (nasopharyngeal swab, oropharyngeal swab, anterior nasal swab, mid-turbinate
swab, nasal washes, nasal aspirates, and bronchoalveolar lavage) [18,19,51,52]. This technique is broken
into two segments: (1) Designing the primer and probe alignment and (2) assay testing. During the
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design process, one primer is selected to detect a variety of coronaviruses including SARS-CoV-2.
A second primer is then selected to detect only SARS-CoV-2. Different primers such as the ORF1a
gene, ORF1b gene, ORF8, RdRp gene, N gene, and E gene are selected to design the gene sequence
of SARS-CoV-2 [51,56]. The number of companies that use each specific target gene is shown in
Figure 2. In the assay testing, there are three primary steps: denaturation, annealing, and extension.
Among PCR-based technologies, RT-PCR is the most common method used by advanced laboratories
and companies to detect SARS-CoV-2. In this approach, SARS-CoV-2 RNA is reverse transcribed
into complimentary deoxyribonucleic acid (cDNA) strands through the exponential amplification
of specific cDNA targets [52]. RT-PCR can be run according to a one-step or two-step procedure.
The one-step method involves running the entire RT step in the same reaction tube as the PCR
reaction [57]. The two-step method first requires the creation of a cDNA strand through the RT reaction.
After the cDNA strand is formed, the PCR reaction is completed in a separate reaction tube, and the
DNA concentration is measured using a fluorophore-quencher probe [18,19,51,52]. Although most
laboratories use a singleplexed RT-PCR technique, the CDC has developed a multiplexed assay
(CDC influenza SARS-CoV-2) that uses RT-PCR to detect the viral RNA of multiple viruses, such as
SARS-CoV-2, influenza A, and influenza B, in a single test. In this assay, each primer and probe
is selected to detect a specific gene sequence. The targeted sequences include the N gene for the
SARS-CoV-2 virus, matrix (M1) gene for the influenza A virus, nsp2 gene for the influenza B virus,
and RNaseP (RP) gene for human nucleic acid [58]. This assay can contribute to new developments in
the detection of SARS-CoV-2 along with other infectious viruses.
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Figure 2. The nu ber of co ercial co panies that use different target regions for designing the
SARS-CoV-2 virus sequence in nucleic acid testing. The ost co on genes are the nucleocapsid
gene, envelope gene, spike gene, ORF1ab gene, embrane gene, replicase polyprotein 1ab gene,
and non-structural protein 2 gene. Among these, the most prevalent targeted gene is the nucleocapsid
gene (73/163 companies). The scientific data was collected from the FDA website on 30 September 2020.
Among nucleic acid tests, RT-PCR techniques have several advantages such as a low LOD,
high sensitivity, and high specificity during the early stages of infection. Compared to other nucleic
acid techniques, RT-PCR only requires samples that contain a small a ount of the expressed gene.
Specifically, the LOD in RT-PCR was estimated to be between 0.91–23 RNA copies/mL [59]. A second
advantage of RT-PCR is its high sensitivity during the first few days of infection. During the first two
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weeks of infection, the sensitivity of RT-PCR was found to be higher than that of other techniques [60].
A third advantage of RT-PCR is its ability to be tailored to detect specific regions of the viral RNA. In a
comparison between three different target regions (RdRp, E and N gene), Corman et al. claimed that
RdRp regions in RT-PCR assays had the lowest LOD [51]. Therefore, the majority of RT-PCR tests use
the RdRp region as the main target sequence. To further investigate the sensitivity of the RdRp region,
Chan et al. compared the sensitivities of RdRp/Hel and RdRp/P2 assays [18]. When using different
types of clinical specimens (i.e., respiratory tract specimens and non-respiratory tract specimens),
they found that the sensitivities of the SARS-CoV-2 RdRp/Hel assays were significantly higher than
the sensitivities of the RdRp-P2 assays. The total confirmed sensitivity of the SARS-CoV-2 RdRp/Hel
assay was 43.6%, and the total sensitivity of the SARS-CoV-2 RdRp/P2 assay was only 28.2% [18].
The specificity of RT-PCR was 100% because of the unique genome sequences chosen in the design
step [28].
Despite the benefits of RT-PCR, this technique also has some disadvantages. The timeline for
detecting the SARS-CoV-2 virus through RT-PCR is limited by the period of infection. The number of
virus particles present in a sample significantly decreases 3 weeks after infection occurs, and a low viral
concentration limits the effectiveness of the test [60]. False negative results might occur depending on
when a sample is collected or differences in patient immune systems. Another disadvantage is the
prevalence of false negative tests in asymptomatic or recovered patients. Finally, PCR-based methods
require long testing times (24 h or a few days), complex equipment, and well-trained technicians to
administer tests and evaluate test results. These requirements limit the testing capabilities of hospitals
and clinical laboratories using this diagnostic technique.
4.1.2. Isothermal Amplification
• Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP)
Another available nucleic acid testing method for detecting the SARS-CoV-2 virus is reverse
transcription loop mediated isothermal amplification (RT-LAMP) [61,62]. The RT-LAMP technique
amplifies the nucleic acid in one step using reverse transcriptase, DNA polymerase, and four to six
oligonucleotides (oligo) of a certain architecture [63,64]. Specifically, some oligos containing a strand
of DNA work as primers for reverse transcriptase. Other oligos are synthesized by DNA polymerase
in the auto-cycling process, which is described in Figure 3. After the nucleic acid has been amplified,
the new DNA products are repeatedly displaced and synthesized as a loop [63]. This auto-cycling
process generates a variety of double-stranded looped DNA structures, which can be detected based
on pH sensitivity [22], fluorescent response [65], and turbidity [62].
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Figure 3. The main principle of the transcription loop mediated isothermal amplification (RT-LAMP)
technique. RT-LAMP starts with the reverse transcription of the backward inner primmer (BIP). The BIP
primer binds to the target sequence on the 3′ end of the RNA template and synthesizes a copy of the
DNA strand (cDNA). Then, by using DNA polymerase, B3 primers bind to the side of the templates,
generate the new cDNA strand, and release the first cDNA strand. This single strand of cDNA is then
looped at the 3′ end and binds to itself. Next, the forward inner primmer (FIP) binds to the 5′ end of
the strand and synthesizes a complementary strand by DNA polymerase. Then, the F3 primer binds to
the end and generates a new double strand of DNA by DNA polymerase. The loop keeps running
as a dumbbell-structure when the FIP or BIP primer initiates DNA synthesis again at the next target
sequence location. The cycle can start at either the forward or backward side of the strand. When it
starts, the strand undergoes self-primed DNA synthesis during the elongation stage of the amplification
process. This amplification can be done in a short amount of time (approximately 1 h) and occurs at a
constant temperature between 60–65 ◦C. Adapted by permission. Copyright of Linda C. et al. [66].
There ar various advantages of the RT-LAMP approach in the detection of the SARS-CoV-2
virus. First, the detection time of SARS-CoV-2 by RT-LAMP is shorter compared to the traditional
RT-PCR. According to Jiang et l., the process time to detect SARS-CoV-2 using RT-LAMP is 2 times
faster than that for qRT-PCR [67]. Due to the formation of a double-stranded loop DNA structure,
the denaturation steps required in RT-PCR are no necessary in RT-LAMP. Moreover, LAMP is a
stable re ction where time-dependent inhibit s re toler ted. As a esult, purification steps a not
required [63,68]. Normally, the temperatu of each step in RT-PCR is different, but the temper ture of
RT-LAMP is constant at 65 ◦C. Thus, the total reaction ime for RT-LAMP is significantly short ned.
S cond, despite the re oval of th RNA isolation step, the specificity of RT-LAMP is high co a ed to
RT-PCR. In an experiment by Dao et al., the specificity of RT-LAMP was 99.5%. The sensitivity was
only 86%, how ver, when the cycle threshold (CT), which is the ycle number when the fluorescence of
a PCR product can be detected above the background signal, was less than 30 [69]. Third, the RT-LAMP
technique d es not require complicated equipment suc as a thermal cycler with real tim fl
measurement capabilities. Af r incuba ion t 65 ◦C, positive results from patient samples can be
determined in 30 min by bs rving a color hang from r d to yellow [64]. Instead of using a specific
instrum t to id ntify th color change, cameras i mobile phones, copy machines, and plate scann rs
with spe trophotometric quantification capabilities an be utilized. Finally, the materials us d f r
RT-LAMP do not need to be refrigerated and can be stored at room te perature [67].
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Despite many benefits, LAMP techniques have several limitations. The limitations are mainly
associated with the low sensitivity of single tests and the optimization of primer design and reaction
conditions. For a RT-LAMP test with RNA extraction, Rodel et al. found that the sensitivity of
RT-LAMP was 75% despite there being no false positive results. The sensitivity was 86.4% when
RT-PCR was used to identify the E gene [70]. When the RT-LAMP and RT-PCR techniques were used
together, the sensitivity and specificity increased to 100% [69,70]. To improve sensitivity, the RT-LAMP
assay could be used with a specific RT-qPCR Ct number. The second disadvantage of RT-LAMP is
that the process for designing primers and probes capable of targeting specific gene sequences can be
complex [63]. As a result, primer optimization might be limited. Third, RT-LAMP has only been able
to detect SARS-CoV-2 in patients with a high viral load. A low RNA input might lead to false negative
results. In one study by Jiang et al. on primer design for LAMP techniques, the virus could not be
detected in four positive patients when the volume of RNA input was 2 µL. This amount was 2.5 times
less than the amount of RNA used for qRT-PCR (5 µL) [67].
• Transcription—Mediated Amplification (TMA)
Similar to the principle of RT-LAMP, transcription-mediated amplification (TMA) is an isothermal
amplification technology that uses reverse transcriptase RNA polymerase, RNaseH, and a T7
promoter-labelled target—a specific primer to detect nucleic acids [71,72]. One of the major differences
between TMA and other nucleic acid techniques (PCR) is the Ribonuclease H (RNaseH) activity in
the reverse transcriptase reaction [71]. RNaseH is an enzyme that can remove RNA from a cDNA
strand. The RNaseH activity in TMA performs the function of the heat denaturing step in RT-PCR [73].
For TMA, the enzyme and primers are first combined together to produce a hybrid fragment of
RNA:DNA with a T7 promoter. This hybrid is considered the first primer. The target RNA strand
from the hybrid fragment is then degraded by RNaseH. Subsequently, the RNA strand is reverse
transcribed into a single-stranded cDNA molecule with a T7 promoter. Finally, a double stranded DNA
molecule is generated by the transcription of T7 RNA polymerase into RNA amplicons. This process is
repeated to generate an exponential amount of RNA amplicons in less than 1 h [66]. The conjugation
between single-stranded nucleic acid torches and RNA amplicons can be detected in real time by a
fluorescence emission [66]. At Hologic’s Panther Fusion company, it was found that TMA tests for
SARS-CoV-2 had a better analytical sensitivity compared to RT-PCR based tests. In their results, the
LOD for SARS-CoV-2 was 5.5 × 104 copies/mL, and the sensitivity was 98.1% in TMA and 96.2% in
PCR [74]. RT-PCR tests done by the CDC were unable to detect the SARS-CoV-2 virus at this viral
concentration [74]. Moreover, due to the ability of TMA to amplify a specific target region of RNA
or DNA, this method has been used to detect other pathogens such as the Hepatitis C virus [75] and
Hepatitis B virus [76].
4.1.3. CRISPR-Based Nucleic Acid Detection
Other molecular techniques that are used to detect SARS-CoV-2 include clustered regularly
interspaced short palindromic repeats (CRISPR) and CRISPR-based (Cas) nuclease systems. A CRISPR
is a segment of DNA with repetitive base sequences that are involved in the prokaryotic
adaptive immune system [77]. The specific process of CRISPR-associated enzymes is described
in Figure 4. Based on this system, a CRISPR/Cas tool has been engineered to edit the genome
in mammalian cells. Currently, there are three types of Cas nucleases: Cas3, Cas12, and Cas13.
CRISPR-Cas3 employs the endonuclease Cas3 enzyme and a multiprotein complex for antiviral
defense [78,79]. Cas3, an intermediate enzyme, is recruited to targeted DNA and mediates DNA
cleavage [78]. Once the recruitment of Cas3 is activated, the target DNA is degraded by 3′ to 5′
exonuclease activity [79,80]. During the process of detecting the SARS-CoV-2 virus, the Cas3 enzyme
contributes to the cleavage of targeted DNA. CRISPR-Cas12 and CRISPR-Cas13, which are Class II
CRISPR-Cas systems, consist of a single nuclease that is related to the cleavage of nucleic acid targets [78].
Cas12 is defined as an RNA-guided DNase that can degrade single-stranded DNA (ssDNA) and induce
Diagnostics 2020, 10, 905 14 of 28
ssDNA cleavage. This mechanism activates a fluorescence emission in the cleavage [25]. Cas13 is
defined as a non-specific RNase that does not activate until the RNA targets are programmed to bind
together. Both CRISPR-associated enzymes can be utilized for targeting and cutting sequences of RNA.
For instance, the DNA endonuclease targeted CRISPR trans reporter (DETECTR) technique utilizes
a CRISPR-Cas12 assay and the RT-LAMP technique for RNA extraction [81]. Moreover, the specific
high-sensitivity enzymatic reporter un-LOCKing (SHERLOCK) technique, utilizes a CRISPR-Cas13
assay with isothermal nucleic acid amplification methods [82]. Therefore, the combination of Cas
nucleases with other nucleic acid tests can speed up the development of diagnostic tests for COVID-19.
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Figure 4. The principle of the clustered regularly interspaced short palindromic repeats (CRISPR)-based
technique for the detection of SARS-CoV-2. CRISPR/Cas12 and CRISPR/Cas13 are used to detect the
viral RNA of SARS-CoV-2. The Cas13 complex binds to the target sequences. This binding activates the
general nuclease enzyme activity of Cas13 to cleave the target sequence. The RNA is then detected
by a fluorescence signal. The activity of Cas12 is similar to the activity of Cas13. One difference
between the two is the positio of the nuclease enzyme. Adapted by permission. Copyright of
Barrangou R. et al. [83].
CRISPR-based technologies have several advantages for the detection of SARS-CoV-2.
First, DETECTR bas d tests have short r process im c mpare o RT-PCR based tests In a
study completed by Broughton et al., the det ction time for DETEC R assay was 45 min, while the
time required for RT-PCR w s 4 [81]. Second, the LOD of the DETECTR technique is low and th
s nsitivity, specificity, and accuracy of th tests are high. The LOD of the DETECTR approach is 10 copies
RNA/µL, and the LOD of RT-PCR tests is 0.91–23 copies RNA/µL [25,81]. Moreover, the ecision of
the measurements used in CRISPR-based pla forms was predicted as 95% for positive tests and 100%
for negative ests [81]. Compared to nucleic acid tests, such as RT-PCR and mNGS, CRISPR-based
as ays have higher sp cificity and sensitivity. According to a study by Hou et al., CRISPR-based assays
could obtain a sensitivity of 100% with no false positive cases PCR based ests only detected 90.4%
of positive cases for a CT range betw en 28.8 and 4 .4 [84]. Third, the ed ting g nome function of
CRISPR technologies allows this platform to be used with other nucleic acid approaches to improve
the det cted sig als. For instance, the association of the Cas13 system and isothermal amplification,
which is called the SHERLOCK chnique, is performed using two separate steps (1) iso hermal
RPA and (2) T7 transcription and Cas13-mediated collateral cleavage of a single-stranded RNA
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reporter [85]. A part of RNA, which is not bound to the target, will activate a fluorescence signal [78].
With the initiation of complex binding and the cleavage of nucleic acid targets during genome
editing, the detected signal in the SHERLOCK technique can be improved. Fourth, CRISPR-based
technologies that contain a lateral flow strip produce test results that can be read with the naked eye.
Currently, the combination of Cas3/Cas12/Cas13 with a nucleic acid platform (LAMP) in a lateral flow
assay is being used to develop a rapid and sensitive diagnostic test for the SARS-CoV-2 virus [81,86].
The use of CRISPR-based technologies also comes with several challenges. First, there are currently
no portable CRISPR-based devices for detecting SARS-CoV-2. A previous study has shown that a
portable SHERLOCK device was able to detect the single stranded RNA of the Dengue and Zika
viruses [87]. Although this technology has not been adapted for the SARS-CoV-2 virus, the success of
CRISPR methods in detecting other pathogens shows that this technology has the potential to be used
with SARS-CoV-2. Second, the off-target effects of CRISPR platforms, which result from unintended
point mutations, deletions, insertions, inversions, and translocations in the assay, might reduce the
accuracy of detecting SARS-CoV-2 nucleic acids. In a study by Anzalone et al., the prime editing
method associated with the Cas9 protein and reverse transcriptase can describe the ingenious path
for a strand of DNA and improve the efficiency of CRISPR-based methods. Even though this editing
approach has not been developed for the SARS-CoV-2 virus, it has the potential to improve the editing
process of DNA templates [88,89]. Other disadvantages are related to mismatch between RNA and
target nucleotides [88].
4.1.4. High-Throughput Technologies
High-throughput sequencing technologies, such as next generation sequencing (NGS) and
amplicon/metagenomic based sequencing (MinION), are able to sequence several DNA molecules at
one time [90]. This technique generates large datasets and gives insight into the cellular genomic and
transcriptomic characteristics of various diseases. These techniques are also used to develop diagnostic
tests for the SARS-CoV-2 virus.
• Next Generation Sequencing (NGS)
NGS is a platform that is used along with other techniques to develop the sequence of several small
DNA fragments simultaneously [91]. Specifically, when NGS is used with bioinformatic techniques,
it has been successful in recognizing and analyzing pathogens. With this technique, one can extract
information from a genome sequence while simultaneously identifying the presence of a virus in a
sample [91]. This commercial technique was developed by Illumina [92]. It can detect the presence
of multiple strains of coronaviruses in a sample and determine the presence of different pathogenic
organisms. Specifically, NGS is able to enrich large amounts of oligo probe panels by hybrid capture
with a comprehensive profile of target regions. In these oligo probes, highly mutagenic regions can be
used to determine how viruses, especially RNA viruses, have evolved [92]. According to Illumina
databases, this technique has a sensitivity 98% and an LOD of approximately 1000 copies/mL [93].
Some of the main disadvantages of NGS include the difficulty of selecting a genome sequence platform,
the need for a highly-trained technician, and the use of computational bioinformatics that requires the
collection of large datasets.
• Amplicon-Based Metagenomic Sequencing
Another high-throughput sequencing technique that is used to detect SARS-CoV-2 is called
amplicon-based metagenomic sequencing. Similar to NGS, this technique uses a combination of
the base amplicon and metagenomic sequencing (MinION) to detect and analyze the microbiome in
nasopharyngeal swabs [94]. This amplicon-based sequencing technique contributes to the detection of
the SARS-CoV-2 virus by improving contact tracing, molecular epidemiological studies, and studies
on viral evolution. This strategy can be used to determine the divergence of a gene sequence.
Metagenomics approaches, including sequence-independent single primer amplification (SISPA),
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are able to provide additional confirmation on the divergence of gene sequence. Compared with
other amplification techniques, the combination of amplicon-based sequencing and SISPA techniques
would provide a lower rate of mutation and recombination with other human viruses. Mutation and
recombination can have significant effects on vaccine and antiviral efficacy. This method was also
used in the West African Ebola virus outbreak to address the characteristics of the viral infection.
Although amplicon-based metagenomic sequencing has the potential to be used for the detection of
SARS-CoV-2, there are several limitations associated with this method. While this method has high
accuracy, sensitivity, and specificity, the time required for viral detection is long (8 h) compared to
some of the other nucleic acid approaches.
4.2. Rapid Diagnostic Tests (RDT)
Due to the limitations of molecular methods, new strategies that use antigens or antibodies in
patient samples to detect SARS-CoV-2 were developed.
4.2.1. Antibody Testing
The typical sample materials used for antibody testing are blood from finger pricks and plasma.
To detect the presence of the SARS-CoV-2 virus, the samples are tested to detect patient antibodies
(IgG, IgM, and IgA) that are specific to viral antigens. The targets used for different serological methods
are presented in Table 2. IgG, IgM, and IgA antibodies are the main targets used for antibody testing.
The viral concentration in the specimens gradually changes over time because of viral replication.
Therefore, the concentration of the viral load is a limitation associated with serological methods.
Currently, there are various point-of-care (POC) diagnostic platforms that are used for SARS-CoV-2
detection. These platforms include rapid lateral flow diagnostic tests, enzyme-linked immunosorbent
assays (ELISA), and proteome peptide microarrays (PPM).
• Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA is commonly used for the detection and quantification of proteins, antigens, antibodies,
glycoproteins, and hormones [95,96]. There are three different types of ELISA assays that are used
to detect SARS-CoV-2. These assays include direct ELISA, indirect ELISA, and sandwich ELISA.
Both direct and indirect ELISA use antigens/antibodies to detect the SARS-CoV-2 virus. In sandwich
ELISA, the viral antigens are detected when they bind to two different antibodies (capture antibodies
and detection antibodies). All three techniques start by coating 96-well plates overnight with human
SARS-CoV-2 proteins from human samples. These proteins bind to the polystyrene plate by an
enzyme-substrate reaction [97]. When the viral protein is present, antiviral antibodies from the patient
samples bind to the plate. The antibody-protein complexes can be detected with an additional tracer
antibody that produces a color signal [96]. The average time to receive a result is approximately 2 to
5 h. In addition to IgG, IgM, and IgA, plasma cytokines, such as IL-6 antibodies, are also used to detect
the presence of SARS-CoV-2 using ELISA [98].
Compared to the nucleic acid testing methods, the ELISA technique has several advantages for
detecting SARS-CoV-2. These advantages include high sensitivity and specificity when an infection
has occurred over 2 weeks prior to testing. In a recent study, Xiang et al. compared the sensitivity,
specificity, and accuracy of SARS-CoV-2 tests that were developed to detect the presence of human
IgG and IgM antibodies [99]. The sensitivity of tests using IgG antibodies and the sensitivity of tests
using both IgG and IgM antibodies were 82.5% and 87.3%, respectively. The specificities of all three
assays (only IgG, only IgM, and a combination of IgG and IgM) were 100%. The accuracy of the tests
increased to 91.8% when both antibody types, IgG and IgM, were used [99]. Zhang et al. also showed
that the sensitivities of ELISA tests using IgG and IgM were high 2 weeks after infection. On day 0
of sampling, the concentrations of IgG and IgM were too low, and the presence of the SARS-CoV-2
virus could not be detected. On day 5, the percentage of positive results from IgG tests increased
from 50% to 81%. The percentage of positive results from IgM tests increased from 81% to 100% [100].
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A second advantage of ELISA is a shorter processing time compared to nucleic acid testing methods.
Third, the use of gold nanoparticles (AuNP) with ELISA improves the sensitivity for colorimetric
detection of an antigen. Ciaurriz et al. found that the sensitivity of AuNP-based ELISA was 5 times
greater than the sensitivity of standard plate type ELISA. The limit of detection, however, was 3 times
lower for AuNP-based ELISA compared to standard plate type ELISA [101]. In addition, results
obtained using AuNP-based ELISA are easier to interpret and can be detected by the naked eye.
A comparison between the different types of ELISA-based assays shows that each type
has distinct advantages for detecting the presence of the SARS-CoV-2 virus in infected patients.
Since direct ELISA only uses a primary antibody, it reduces the risk of cross-reactivity with a
secondary antibody. The procedure for direct ELISA is also faster because there are fewer steps.
Indirect ELISA is advantageous because it is very flexible and different primary antibodies can be
selected. Sandwich ELISA has the highest sensitivity among the three types. The use of two monoclonal
antibodies improves the sensitivity and specificity of the test for the SARS-CoV-2 nucleocapsid protein.
In a previous study by Fung et al., the combination of monoclonal antibodies (mAbs) in a sandwich
ELISA assay enabled differentiation and correct identification of the MERS-CoV S protein and N
protein [102].
In addition to its advantages, there are also several limitations of using ELISA for the detection of
SARS-CoV-2. First, some commercial testing kits are only intended for research applications and have
not been used in clinical settings yet. Second, monoclonal antibodies cannot identify the mutated virus
in ELISA. According to Niikura et al., one monoclonal antibody can only identify three of the four
subtypes of the Ebola virus. As a result, it is possible that variations in the SARS-CoV-2 virus may lead
to cross-reactivity [103]. The SARS-CoV-2 virus structure has six different subtypes, so a false positive
or negative result could possibly occur.
• Chemiluminescence Immunoassay (CLIA)
Chemiluminescence immunoassay is another technique used to determine the presence of
antibodies in patient serum. Currently, this technique uses magnetic, protein-coated microparticles.
The principle of CLIA is similar to the principle of direct ELISA. The main difference is the use of
luminescence to read the results. There are several advantages of the CLIA method. First, due to the
high signal intensity and absence of interfering emissions, CLIA can obtain higher sensitivities and
specificities compared to other serological methods including LFIA and ELISA. For the measurement of
IgG/IgM, the pooled sensitivity of CLIA was 97.8%. The sensitivity of ELISA was only 84.3%, and the
sensitivity of LFIA was only 66% [104]. The use of magnetic and protein-coated microparticles with
CLIA increases the sensitivity of the technique. According to the Liu et al., when using a microparticle
CLIA approach, the sensitivity of the IgM measurement was 72.3%, and the sensitivity of the total
antibody measurement was 90.8% [105]. However, when using a peptide-based magnetic CLIA
assay, the sensitivity of the IgG and IgM measurements are only 71.4% and 57.2%, respectively [106].
Some of the significant limitations of CLIA include the high cost, complex instrumentation, and highly
trained technicians.
• Lateral Flow Immunoassay (LFIA)
Lateral flow immunoassay (LFIA) is a qualitative chromatographic assay that determines whether
a target analyte, such as a biomarker, is present in an unknown sample. The typical sample materials
used with this technique are blood from finger pricks, saliva, urine, and nasal swab fluids. To detect
the presence of the SARS-CoV-2 virus, these samples are tested to detect patient antibodies (IgG, IgM,
and IgA) that are specific to viral antigens in various targeted regions. The target antigens include S
glycoproteins (S1 and S2 subunits, RBD) and N proteins [64,107]. LFIA is typically constructed as a
strip including a sample pad, a conjugate pad, a membrane, a detection zone, and an adsorbent pad
(Figure 5). The principle of LFIA is based on the movement of a fluid sample through different zones
of a strip via capillary forces. To detect SARS-CoV-2 related antibodies, a viral antigen is conjugated to
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gold or fluorescent particles. The antibody in the patient sample binds to the viral antigen, which has
been immobilized on the conjugate pad. If SARS-CoV-2 antibodies are present in a sample, they will
bind to the gold-conjugated SARS-CoV-2 antigen. The antibody-antigen complex then flows to the
capture zone of the device. In the capture zone, the antibody-antigen complex binds to another
antibody which induces color formation. Many advanced laboratories and companies are developing
kits based on the LFIA approach. These kits use different containers, such as cassettes and casings
similar to those used for pregnancy tests.
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Figure 5. Lateral flow immunoassay for the detection of anti-SARS-CoV-2 antibodies [21]. The sample
fluid flows laterally along the strip, which includes different zones such as conjugation pad, adhesive
pad, and absorption pad. The conjugation pad includes antibodies for the target analyte and antibodies
conjugated with signal molecules (fluorescent particles and gold particles). The nitrocellulose membrane
contains the testing lines (IgG and IgM lines) and the control line. The last zone is the absorption pad,
which prevents the backflow of the liquid. Adapted by permission. Copyright of Li Z. et al. [21].
There are several advantages of using LFIA to determine the presence of the SARS-CoV-2 virus
through antigen or antibody testing. First, LFIA is able to produce results quickly. Specifically, LFIA
takes approximately 10 to 30 min to detect SARS-CoV-2. The detection time for traditional ELISA is 2
to 5 h. Second, the sensitivity and accuracy of LFIA for the detection of SARS-CoV-2 increases 2 weeks
after infection. According to Adam el al., the sensitivity of a LFIA device increased from 61% to 88%,
10 days after the onset of symptoms [23]. In another study by Niikura et al., the sensitivity of LFIA was
found to b 100%, 3 weeks after th onset of symptoms [107]. Third, LFIA is inexpensive, and results
can be detected by the naked eye.
Despite these benefits, there are some concerns with the use of LFIA in commercial products [108].
First, the sensitivity of LFIA was low compared to other serological methods. When using the same
amount of sample material, LFIA had a sensitivity of 66%. This sensitivity was lower than other
serological methods, which had sensitivities greater than 80% [104]. A comparison between different
types of LFIA kits showed that the sensitivities of commercial LFIA kits (average 65%) was lower
than e nsitivities of kits used in laborat ries (average 88.2%) [104]. Second, it can be challenging
to control the velocity of the fluid and the capillary forces during the process of antigen capture.
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Third, a previous report described that the pore size of the porous media can limit the fluid flow [109].
Fourth, the analysis time depends on the nature of the sample. For instance, storage conditions,
fluid viscosity, and surface tension can all impact the sample analysis time [110]. Prolonged storage
can possibly lead to false negative results. In a study by Wu et al., nine serum samples, which were
collected from two patients with SARS-CoV-2, were stored for more than 9 days at −20 ◦C before
an antibody response test was run. The results showed that two of the nine samples, which were
taken on day 2 and 7 after symptom onset, showed no antibody response. The rest of the samples all
successfully showed the correct results.
4.2.2. Antigen Testing
Antigen testing is another approach used to detect the presence of the SARS-CoV-2 virus during
an active infection. An evaluation of the most recent authorized SARS-CoV-2 antigen tests that were
issued an EUA by the FDA are presented in Table 3. According to recent literature reports and
commercially available product manuals, N proteins and S proteins were the most common targets
used in antigen-based testing and serological methods. According to Baker et al., glycans are used
as the capture unit when detecting SARS-CoV-2 S proteins with the LFIA approach [50]. Similar to
antibody testing, antigen testing is performed using LFIA in two main forms (singleplex and multiplex).
The typical sample materials used are nasal swabs and nasopharyngeal swabs. To determine the
presence of the SARS-CoV-2 virus, these samples are tested to detect specific antigens in various
targeted regions (S glycoproteins and N proteins). Currently, the EUA and FDA have approved N
proteins as a target region for antigen testing kits. The LOD for N proteins is within the range of
1.0 × 102 TCID50/mL to 4.5 × 105 TCID50/mL. The advantages of antigen testing include rapid results,
high sensitivity and specificity, inexpensive cost, and naked-eye result readout. According to a report
of approved antigen testing kits from the FDA, the total time needed to receive results is less than
20 min. The sensitivity of these testing kits ranges from 84% to 97.6%, and the specificity is 100% based
on a report from CDC [46].
4.2.3. Proteome Peptide Microarray (PPM)
The proteome microarray technique is typically used to investigate the interactions of antibodies
and proteins at the amino acid level [26,111]. This technique provides information on viral protein
epitope identification and specificity mapping for the binding of antibodies to SARS-CoV-2 proteins.
Recently, high-density peptide microarrays have been used to analyze the interaction profiles of
antibodies in the human serum [26]. By providing an understanding of antibody responses to
SARS-CoV-2 proteins, this technique can help determine the infection signals. Several commercially
available antibodies that were used for SARS-CoV are also being used for SARS-CoV-2. The main
advantage of the PPM method is that it can provide a holistic view of antibody responses to viral proteins.
According to Jiang et al., the PPM method can identify the responses of IgG/IgM antibodies to N, S1,
and S2 proteins on the SARS-CoV-2 virus. As a result, 100% of patients had IgG/IgM responses to the
virus at the N protein and S1 protein targets. Meanwhile, the S2 target did not receive any responses [112].
Despite some advantages, there are several limitations with this technology. First, the epitopes of several
SARS-CoV-2 antibodies may have been modified by post-translational changes or conformations.
These modifications may affect the accuracy of the detection [26]. Second, many new strains of
SARS-CoV-2 have been identified [113]. The test results may change depending on which viral strain
is present in the sample. Finally, this technology has only been used for research, and it has not been
approved for clinical diagnostic tests.
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4.3. Medical Imaging
Computed tomography (CT) scans can also be used in the clinical diagnosis of SARS-CoV-2.
This technique is used because it has a higher sensitivity than the currently available RT-PCR
methods [19,114–116]. The detection of the virus in a patient is based on cross sectional X-ray images
of the chest. New images are captured during each stage of infection (early stage, intermediate stage,
and late stage) [116]. In CT scans, bilateral and peripheral ground-class opacities were found to be
common symptoms of the viral infection. The changes in the lung images are analyzed in light of how
much time has passed since symptoms first appeared. For patients who experienced acute-phase diffuse
alveolar damage (≤7 days from the onset of respiratory failure), the SARS-CoV-2 virus was found
in the pulmonary pneumocytes, ciliated airway cells, and upper airway epithelium. The maximum
change in lung shape and the highest frequency of ground-glass opacities were observed 10 days after
the onset of symptoms [116]. According to Yang et al., patient chest exams via X-ray demonstrated
the highest positivity rate (100%) 8 to 14 days after the onset of symptoms [117]. This technique is
not a viable option if a patient has pre-existing lung complications. In addition, this method is not
suitable for asymptomatic carriers. Finally, it requires highly trained personnel and sophisticated
instrumentation to be performed and evaluated.
4.4. Potential Diagnostic Tests
4.4.1. Vertical Flow Assays (VFA)
Another approach that can be used to detect SARS-CoV-2 is a vertical flow assay (VFA).
This technique is similar to a lateral flow assay, but it uses a vertical flow pattern instead. Both assays
require the formation of an antibody-antigen complex, immobilization of the capture antibody
onto a readout layer, and the immobilization of the labelled detection antibody for the production
of a color signal [109]. The main advantages of vertical flow assays include the use of external
forces, such as gravitational forces and capillary forces, and the ability to easily multiplex the assay.
Additionally, the VFA sensor response is faster than that of a lateral flow assay, and the test results
can be evaluated by untrained users [108]. The pore size of the membrane and the optimized flow
rate determines the sensitivity of the test. VFA has a faster detection time than LFA because of the
immediate reaction between the specific antigen and the conjugated detection antibody. The signal
can be detected with the naked eye, or it can be quantified using imaging techniques, such as those
used in smartphone readers [108]. According to Chen et al., vertical flow can increase the flow rate
and decrease the required pore size of a membrane. As a result, vertical flow methods can be up to
5 times more sensitive than lateral flow methods [109]. Vertical flow is an alternative configuration
that can address the pore size, velocity control, and time limitations associated with lateral flow.
Therefore, VFA can possibly be used to detect the SARS-CoV-2 virus.
4.4.2. Microfluidic Devices
Microfluidic devices can also be considered for the diagnosis of SARS-CoV-2. These devices
typically consist of a centimeter-scale chip with micrometer-scale channels and chambers [28].
Microfluidic devices have been constructed using materials such as paper, polymers, and glass.
The advantages of microfluidic devices include the ability to provide quick results, portability, and the
ability to use small sample volumes. Previous research has shown that microfluidic platforms are
able to detect pathogens such as the human immunodeficiency virus (HIV), the hepatitis B virus
(HVB), and the Zika virus (ZIKV) [118]. Moreover, these devices have been developed in combination
with methods such as RT-PCR, RT-LAMP, LFIA, and ELISA. In a study completed by Qui et al.,
the combination of RT-PCR and microfluidics was able to detect the H1N1 virus in less than 30 min.
Standard RT-PCR techniques require up to 24 h to detect the H1N1 virus. In this work, the capillary
tubes in the microfluidic devices were fabricated using injection molding. A smartphone was then
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used to image and quantify the fluorescent signal from the diagnostic test [119]. Microfluidics-based
approaches have a high potential to be used for the detection of SARS-CoV-2.
5. Test Considerations
Although disadvantages and advantages are described for each approach, no universal diagnostic
test is available to detect the SARS-CoV-2 virus. There are still several factors that need to be considered
before a universal test can be developed. These factors include the analytical results, the conditions
for sample storage, and the population samples. First, the analytical results such as the sensitivity,
specificity, and accuracy of different testing methods depends on how much time has passed since the
infection occurred. Nucleic acid testing can identify the viral load during the early stages of infection,
serological testing is able to diagnose patients who were previously infected or are actively infected,
and the imaging techniques have been developed for patients with mild to severe symptoms [120,121].
Second, there is a lack of information regarding the external storage conditions for human samples.
Storage conditions, such as temperature and storage time, can affect the precision of diagnostic
tests [122]. Different sample types require different collection methods and storage conditions [123].
In a previous study by Wu et al., two false negative results for SARS-CoV-2 occurred in a LFIA-based test
with long sample storage times [107]. The incorrect results might have originated from the degradation
of proteins while the sample was in storage. According to a study by Shenouda et al., the denaturation
process of nucleotides, carbohydrates, small peptides, and free amino acids in proteins are significantly
impacted by cold temperatures [124]. Information about the external storage conditions for samples
should be studied to increase the accuracy of test results. In another study by Bevins et al., it was
found that antibody proteins can be kept in storage at freezing temperatures with desiccants [125].
More information about sample collection and storage should be indicated to increase the accuracy of
the result. Third, a standard sample size for each technique has not been determined due to the lack of
a large population to study and a lack of information on asymptomatic cases. In a comparison between
blood and swab samples in RT-PCR, the positive rates were 15%–30% and 14%–38%, respectively [126].
However, the samples were obtained from only 23 patients for blood tests and 15 patients for swab
tests [126]. Samples should be collected from a wider population to validate this result. Third, there are
still many questions surrounding viral replication and evolution as a result of re-infection cases.
6. Conclusions
Over the last few months, industrial companies and scientific laboratories have developed a
variety of different tests to diagnose patients with the SARS-CoV-2 virus. The latest research is focused
on developing efficient tests that are inexpensive, rapid, reliable, and have high sensitivity, specificity,
and accuracy. Most of the published papers and commercial products have explored different types of
molecular assays, serological methods, and imaging techniques for detecting SARS-CoV-2. RT-PCR is
the most common nucleic acid technique for detecting viral RNA for SARS-CoV-2. Different types of
amplification assays, including CRISPR-related technologies and other high-throughput sequencing
methods, have been developed to increase the sensitivity and specificity of these diagnostic tests.
Moreover, POC testing kits that are rapid and simple-to-use have also been developed.
Despite minor drawbacks, some of the diagnostic techniques work well in clinical settings.
Other newly developed techniques demonstrate promise for clinical use. By using the knowledge
gained from previous outbreaks and the currently available strategies, diagnostic tests for SARS-CoV-2
will continue to be developed and improved.
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